79P Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, single-arm, phase II study. (December 2022) - Wu, X.; Xia, L.; Wang, J.; Wang, C.; Zhang, Q.; Zhu, J.; Rao, Q.; Cheng, H.; Liu, Z.; Y. Yin,; Ai, X.; Gulina, K.; et al.